CN110038119A - A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect - Google Patents

A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect Download PDF

Info

Publication number
CN110038119A
CN110038119A CN201910350090.XA CN201910350090A CN110038119A CN 110038119 A CN110038119 A CN 110038119A CN 201910350090 A CN201910350090 A CN 201910350090A CN 110038119 A CN110038119 A CN 110038119A
Authority
CN
China
Prior art keywords
parts
weight
pharmaceutical composition
synanthrin
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910350090.XA
Other languages
Chinese (zh)
Inventor
狄志鸿
张昌娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Zejian Pharmaceutical Technology Co Ltd
Original Assignee
Hangzhou Zejian Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zejian Pharmaceutical Technology Co Ltd filed Critical Hangzhou Zejian Pharmaceutical Technology Co Ltd
Priority to CN201910350090.XA priority Critical patent/CN110038119A/en
Publication of CN110038119A publication Critical patent/CN110038119A/en
Priority to PCT/CN2020/087150 priority patent/WO2020221192A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention belongs to biomedicine fields, and in particular to a kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect;The pharmaceutical composition is prepared by following raw materials: ocean fish oligopeptide, synanthrin, sodium citrate, potassium citrate and citric acid.Studies have shown that composition of the present invention has antifatigue, anti-trioxypurine pharmacological action, further illustrate, the present composition can be used for patient with gout caused by fatigue.

Description

A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect
Technical field
The invention belongs to biomedicine technical fields, specifically contain a kind of medicine group with anti-trioxypurine and antifatigue effect Close object.
Background technique
Gout is a kind of common and complicated arthritis type, and all age group may suffer from this disease, male's disease incidence Higher than women.Often there is sudden arthritis at night in patient with gout, and morbidity is anxious, and serious pain occurs in joint part Bitterly, oedema, redness and inflammation, feeling of pain slowly mitigates until disappearance, takes several days or a few weeks are differed.When panic attacks, suffer from Person can ache in midnight sleep soundly to wake up, and has patient to describe feeling of pain and is burnt equally similar to big toe.The joint of most commonly-occurring disease is Big toe (medical terminology: first metatarsal bone), but the joint fallen ill is without being limited thereto, is also common in joint, the knee, ancon of hand Deng.The eventually red and swollen, inflammation of the joint of morbidity is organized to soften after oedema, and limitation of activity finally influences daily life.
Cause gout essential reason be internal uric acid level raising, cause lithate in joint and renal tract Deposition.Usually, the main reason for causing gout includes but is not limited to: (1) dietary reasons.Too many meat and sea are eaten Fresh, after having drunk happily excessive beer, the uric acid level of human body is increased, it is possible to cause uric acid mineralization;(2) fat.It is fat Caused consequence is the increase of internal uric acid, and kidney can not thoroughly remove extra uric acid;(3) some drugs have been taken.These Drug will lead to internal uric acid level and increase;(4) family history.If household suffers from gout, the probability of your illness also can be big It is big to increase.
By the acute arthritis breaking-out condition survey to a large amount of patient with gout, discovery fatigue and high purine diet are the most Common inducement.Have plenty of continuously work extra shifts or extra hours work, often travel on business trips or move the new home when because excessive fatigue morbidity, Some is fallen ill after being satiated with food a large amount of fishes, meat product.
Therefore, researching and developing one kind not only has anti-trioxypurine but also has antifatigue product, has important clinical significance.
Summary of the invention
For these reasons, applicant passes through multiple creative research, obtains a kind of new pharmaceutical composition, the composition It is to be prepared by ocean fish oligopeptide, synanthrin, sodium citrate, potassium citrate and citric acid, studies have shown that of the present invention Composition have antifatigue, anti-trioxypurine pharmacological action, further illustrate, caused by the present composition can be used for fatigue Patient with gout.
Special doctor's food of the present invention, refer to must under doctor or clinical nutrition's teacher guidance, it is individually edible or and its His food is matched.Refer to meet limited feed, Disorder of Digestion and A orption, metabolic disorder or particular disease states crowd couple The formula food being formulated specially is processed in the special requirement of nutrient or diet.Spy doctor's food is not drug, but is not normal The ordinary food that people eats, but pass through clinician and a large amount of medical research of nutritionists, the objective fact with science is According to the special formula food developed, produced.When target group can not feed full diet or can not meet it with ordinary meal When nutritional need, special medicine purposes formula food can be used as a kind of nutritional supplementation approach, play the role of nutritional support.The food Product are unable to the therapeutic effect of alternative medicine, and product must not also claim prevention of disease and treatment function.
Ocean fish oligopeptide of the present invention meets " ocean fish oligopeptide powder (GB/T 22729-2008) ", marine fish Collagen oligopeptide is using pollution-free or the relatively small deep-sea fish of pollution skin, bone as raw material, and purification is process.
Synanthrin of the present invention refers to inulin or natural levulan, and to be with jerusalem artichoke (Jerusalem artichoke) rhizomes be or witloof is former Material, removes removing protein, colloid, crude fibre and minerals, extracts through water, ion exchange, and film filtering, the production technologies such as spray drying obtain To synanthrin.
The present invention is achieved through the following technical solutions.
A kind of pharmaceutical composition, the pharmaceutical composition are prepared by following raw materials: ocean fish oligopeptide, synanthrin, lemon Sour sodium, potassium citrate and citric acid.
Preferred pharmaceutical composition, wherein ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and citric acid 1-5 parts by weight.
Further preferred pharmaceutical composition, wherein 3 parts by weight of ocean fish oligopeptide, 15 parts by weight of synanthrin, potassium citrate 4 parts by weight of 14 parts by weight, 12 parts by weight of sodium citrate and citric acid.
The application of pharmaceutical composition described above in preparation treatment gout drug.
Pharmaceutical composition described above is preparing the application in anti-trioxypurine drug.
Pharmaceutical composition described above is preparing the application in antifatigue drug.
Pharmaceutical composition described above is applied in preparing anti-trioxypurine spy doctor's food.
A kind of pharmaceutical composition for treating gout effect, the pharmaceutical composition are prepared by following raw materials: marine fish is low Poly- peptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 weight of synanthrin Part, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
A kind of pharmaceutical composition with anti-trioxypurine effect, is prepared in the pharmaceutical composition by following raw materials: ocean Fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and lemon Lemon acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 weight of synanthrin Measure part, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
A kind of pharmaceutical composition with antifatigue effect, the pharmaceutical composition are prepared by following raw materials: marine fish Oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and lemon Sour 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 weight of synanthrin Part, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
Ocean fish oligopeptide of the present invention meets " ocean fish oligopeptide powder (GB/T 22729-2008) ", marine fish Collagen oligopeptide is using pollution-free or the relatively small deep-sea fish of pollution skin, bone, meat as raw material, and purification is process.This hair The bright ocean fish oligopeptide are as follows: marine fish skin collagen oligopeptide, Marine fishbone collagen oligopeptide, ocean fish oligopeptide.
Synanthrin of the present invention refers to inulin or natural levulan, be using jerusalem artichoke (Jerusalem artichoke) rhizomes or witloof as raw material, Removing protein, colloid, crude fibre and minerals are removed, are extracted through water, ion exchange, film filters, and the production technologies such as spray drying obtain Synanthrin.
Pharmaceutical composition of the present invention can be prepared into oral solid formulation, and other supplementary material systems can also be added For at granule.
D-sorbite, isomaltoketose (palatinose, isomery sugarcane can also be added in pharmaceutical composition of the present invention Sugar), nutrition enhancer premix, one or more of Sucralose, be prepared into composite powder.
The nutrition enhancer premix includes the component of following parts by weight: 130-140 parts of taurine, Catergen 20- 230 parts, 0-20 parts of vitamin e1,0.5-1 parts of beta carotene, vitamin B22-3 parts, vitamin B61-2 parts, pantothenic acid 5-10 Part, 0.05-2 parts of folic acid.
Preferred nutrition enhancer premix includes the component of following parts by weight: 140 parts of taurine, 225 parts of vitamin C, 18 parts of vitamin E, 0.6 part of beta carotene, vitamin B22.2 parts, vitamin B61.81 parts, 8 parts of pantothenic acid, folic acid 0.06 Part.
Supplementary material source of the present invention is shown in Table 1.
The supplementary material source of the present invention of table 1
The present invention is to be aided with sodium citrate, potassium citrate and citric acid based on ocean fish oligopeptide and synanthrin, for easy It is taken in the patient with gout of fatigue, is to carry out using rather than ordinary food under the guidance of clinician or nutritionist;In sea On the basis of foreign fish oligopeptide, synanthrin, sodium citrate, potassium citrate and citric acid, D-sorbite, different malt ketone can also be added One or more of sugared (palatinose, isomery sucrose), nutrition enhancer premix, Sucralose.
Specific embodiment
Below the technical scheme of the invention is illustrated by a specific example, but the scope of the present invention is not limited thereto.
Content described in this specification embodiment is only enumerating to the way of realization of inventive concept, protection of the invention Range should not be construed as being limited to the specific forms stated in the embodiments, and protection scope of the present invention is also and in art technology Personnel conceive according to the present invention it is conceivable that equivalent technologies mean.Although embodiment of the invention below is retouched It states, but the invention is not limited to above-mentioned specific embodiments and applications field, following specific embodiments is only to show It is meaning property, guiding, rather than it is restrictive.Those skilled in the art under the enlightenment of this specification and are not taking off In the case where the range protected from the claims in the present invention, a variety of forms can also be made, these belong to the present invention The column of protection.
The following tests of the present invention are on the basis of multiple creative test, with the claimed technical solution of the present invention Based on, the conclusive test of the research staff of summary.Quantitative test in following embodiment, is respectively provided with three repeated experiments, Data are the average value or mean+SD of three repeated experiments.
Following tests entrust grand reputation wing Yao (Beijing) Science and Technology Ltd. to complete by applicant.
Test the influence of 1 pair of mouse hyperuricemia
Test group:
Test 1 group: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g;
Test 2 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, sodium citrate 2.6g;
Test 3 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 2.6g;
Test 4 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, natrium malicum 1.73g;
Test 5 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, sodium bicarbonate 0.74g;
Test 6 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 1.4g, sodium citrate 1.2g.
Test 7 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 2.6g, citric acid 0.4g.
Test 8 groups: Marine fishbone collagen oligopeptide 0.3g, synanthrin 1.5g, potassium citrate 1.4g, sodium citrate 1.2g and lemon Lemon acid 0.4g.
Test method: kunming mice, male, 18~22g of weight is random to be grouped, blank control group, model group, test group, Every group 10, in addition to naive mice, equal stomach-filling Oteracil Potassium (100mg/kg) modeling of other group of every morning, of the present invention group every Give raw material 3.5g/kg its afternoon, the distilled water of same volume is given in model group stomach-filling in afternoon.Each group is administered once daily, and is given altogether Medicine 30d, the 30d during administration carry out index of correlation detection.Indexs measure: fasting 12h (can't help before formal experiment starts Water), and blood 1mL first is taken from eye socket before administration, after being placed at room temperature for 2h, centrifugation (4000r/min, 15min) separates serum, put- 20 DEG C spare, horizontal for the serum UA before test experience.Take blood examination to survey with same method within the 30d days in administration, after 30d in addition to It is horizontal to detect UA.
Test result is shown in Table 1:
Influence of the table 1 to hyperuricemia mouse uric acid
Note: P < 0.05 * * P < 0.01, * compared with model group;##P < 0.01 compared with 0d, #P < 0.05.
Conclusion (of pressure testing): after raising 30d, compared with blank group, model group UA horizontal significantly raised (p < 0.01), explanation is made Mould success;Compared with model group, the UA that 8 groups of 2 groups-test of test can reduce hyperuricemia mouse is horizontal, has significant Sex differernce (P < 0.05), although and testing 1 group and analyzing the UA level for having reduction hyperuricemia mouse, and model from data Group is relatively without statistical difference;It absolutely proves, 8 groups of 2 groups-test of test has certain anti-trioxypurine effect.
Test 2 anti-fatigue tests
Test method: Kunming mouse, weight 18-20g are taken.Random grouping, every group 10, control group gives physiological saline 0.2ml/20g.1 each test group gastric infusion is tested, mouse is quickly put into advance by dosage 3.5g/kg after administration 1 hour In the swimming pool got ready, record mouse enters pond and starts to the time no longer swum.It the results are shown in Table 2.
Trial drug: see test 1.
2 anti-fatigue test result of table
Note: compared with the control group, P < 0.05 * * P < 0.01, *.
Test result: show 1 group to 7 groups of test of test in terms of antifatigue from above-mentioned test data, have with control group aobvious It writes sex differernce (P < 0.05);And 8 groups are tested at antifatigue aspect, there is extremely significant difference (P < 0.01) with control group.
Test 3 stability tests
Test method:
(1) exposure experiments to light: test 1- is taken to test 7 raw materials, loose to divide in small culture dish, thickness about 5mm.It places it in Drug strong illumination chamber is placed 10 days under the conditions of Yu Zhaodu 4500Lx ± 500Lx, in the 5th day and the 10th day sample detection Relative molecular weight is lower than the content of 1000u oligopeptide (small peptide), as a result compared with 0 month data.
(2) hot test: taking test 1- to test 7 raw materials, be placed in small beaker, sealing film sealing.Place it in electric heating drum Wind drying box is placed 10 days under the conditions of 60 DEG C ± 1 DEG C, is lower than 1000u in the 5th day and the 10th day sample detection relative molecular weight The content of oligopeptide (small peptide), as a result compared with 0 month data.
(3) high humidity test: take test 1- test 7 raw materials, be placed in small beaker, be respectively placed in fill NaCl saturated solution and KNO3The close drying device of saturated solution, damp condition are respectively RH75%.It is respectively placed in electric drying oven with forced convection, 25 It is placed 10 days under the conditions of DEG C ± 1 DEG C, is lower than 1000u oligopeptide (small peptide) in the 5th day and the 10th day sample detection relative molecular weight Content, as a result compared with 0 month data.
Trial drug: 7 groups of 1 group-test are tested in test 1
Detection method: according to the detection method in GB/T 22729-2008.
Test result is shown in Table 3, table 4, table 5.
3 exposure experiments to light result of table
4 high temperature test result of table
5 high humidity test result of table
Conclusion (of pressure testing): it is above-mentioned experiments have shown that, Marine fishbone collagen oligopeptide and synanthrin composition stability are preferable, and again plus Enter sodium citrate or potassium citrate or citric acid or natrium malicum or sodium bicarbonate, will lead to Marine fishbone collagen oligopeptide in height It degrades under wet environment, content is caused not meet quality criteria requirements (standard are as follows: be more than or equal to 85%);And be added sodium citrate, The group of potassium citrate and citric acid, Marine fishbone collagen oligopeptide are hardly degraded;Therefore, the comprehensive pharmacology examination of inventor It tests, 8 groups of retention test are raw material of the present invention.
Prepare embodiment
Embodiment 1
D-sorbite 3000g, synanthrin 1500g, isomaltoketose 1000g, potassium citrate 1000g, sodium citrate 1000g, Citric acid 100g, ocean fish oligopeptide 200g, nutrition enhancer premix 50g, Sucralose 10g.Above-mentioned raw materials mixing is complete To obtain the final product.
Embodiment 2
D-sorbite 4000g, synanthrin 2000g, isomaltoketose 1500g, potassium citrate 1500g, sodium citrate 1500g, Citric acid 500g, ocean fish oligopeptide 500g, nutrition enhancer premix 300g, Sucralose 50g.Above-mentioned raw materials mixing is complete To obtain the final product.
Embodiment 3
D-sorbite 3630g, synanthrin 1500g, isomaltoketose 1500g, potassium citrate 1400g, sodium citrate 1200g, Citric acid 400g, ocean fish oligopeptide 300g, nutrition enhancer premix 50g, Sucralose 20g.Above-mentioned raw materials mix to obtain the final product.
Embodiment 4
D-sorbite 3200g, synanthrin 1650g, isomaltoketose 1200g, potassium citrate 1200g, sodium citrate 1150g, Citric acid 120g, ocean fish oligopeptide 220g, nutrition enhancer premix 65g, Sucralose 12g.Above-mentioned raw materials mix to obtain the final product
Embodiment 5
D-sorbite 3850g, synanthrin 1850g, isomaltoketose 1400g, potassium citrate 1450g, sodium citrate 1350g, Citric acid 450g, ocean fish oligopeptide 400g, nutrition enhancer premix 250g, Sucralose 40g.
In above-described embodiment in nutrition enhancer premix raw material proportionate relationship are as follows: 140 parts of taurine, vitamin C 225 parts, 18 parts of vitamin E, 0.6 part of beta carotene, vitamin B22.2 parts, vitamin B61.81 parts, 8 parts of pantothenic acid, folic acid 0.06 part.
Ocean fish oligopeptide of the present invention meets " ocean fish oligopeptide powder (GB/T 22729-2008) ", marine fish Collagen oligopeptide is using pollution-free or the relatively small deep-sea fish of pollution skin, bone, meat as raw material, and purification is process.This hair The bright ocean fish oligopeptide are as follows: marine fish skin collagen oligopeptide, Marine fishbone collagen oligopeptide, ocean fish oligopeptide.
Synanthrin of the present invention refers to inulin or synanthrin or natural levulan, is with jerusalem artichoke (Jerusalem artichoke) rhizomes or witloof For raw material, removing protein, colloid, crude fibre and minerals are removed, are extracted through water, ion exchange, film filtering, the production work such as spray drying Skill obtains synanthrin.
Pharmaceutical composition of the present invention can be prepared into oral solid formulation, and other supplementary material systems can also be added For at granule.
Pharmaceutical composition (composition including embodiment) of the present invention, can be used alone, to treat or in advance Anti- gout breaking-out, can also be with the drug combination, such as Febustat, colchicin, Allopurinol, Benzbromarone etc. for the treatment of gout Drug.

Claims (10)

1. a kind of pharmaceutical composition, it is characterised in that the pharmaceutical composition is prepared by following raw materials: ocean fish oligopeptide, chrysanthemum Sugar, sodium citrate, potassium citrate and citric acid.
2. a kind of pharmaceutical composition according to claim 1, wherein ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 are heavy Measure part, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight and citric acid 1-5 parts by weight.
3. a kind of pharmaceutical composition according to claim 1, wherein 3 parts by weight of ocean fish oligopeptide, 15 parts by weight of synanthrin, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
4. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition Treat the application in gout drug.
5. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition Application in anti-trioxypurine drug.
6. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition Anti-trioxypurine spy cures to apply in food.
7. a kind of pharmaceutical composition according to claim 1-3, it is characterised in that prepared by the pharmaceutical composition Anti-trioxypurine spy cures to apply in food.
8. a kind of pharmaceutical composition for treating gout effect, it is characterised in that the pharmaceutical composition is prepared by following raw materials: Ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 parts by weight With citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, synanthrin 15 parts by weight, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
9. a kind of pharmaceutical composition with anti-trioxypurine effect, it is characterised in that the pharmaceutical composition prepared by following raw materials and At: ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 weight Measure part and citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 parts by weight of synanthrin, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
10. a kind of pharmaceutical composition with antifatigue effect, it is characterised in that: the pharmaceutical composition prepared by following raw materials and At: ocean fish oligopeptide 2-5 parts by weight, synanthrin 15-20 parts by weight, sodium citrate 10-15 parts by weight, potassium citrate 10-15 weight Measure part and citric acid 1-5 parts by weight;Preferred pharmaceutical composition is prepared by following raw materials: 3 parts by weight of ocean fish oligopeptide, 15 parts by weight of synanthrin, 4 parts by weight of 14 parts by weight of potassium citrate, 12 parts by weight of sodium citrate and citric acid.
CN201910350090.XA 2019-04-28 2019-04-28 A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect Pending CN110038119A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910350090.XA CN110038119A (en) 2019-04-28 2019-04-28 A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect
PCT/CN2020/087150 WO2020221192A1 (en) 2019-04-28 2020-04-27 Pharmaceutical composition having uric acid-lowering and anti-fatigue effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910350090.XA CN110038119A (en) 2019-04-28 2019-04-28 A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect

Publications (1)

Publication Number Publication Date
CN110038119A true CN110038119A (en) 2019-07-23

Family

ID=67280069

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910350090.XA Pending CN110038119A (en) 2019-04-28 2019-04-28 A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect

Country Status (2)

Country Link
CN (1) CN110038119A (en)
WO (1) WO2020221192A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221184A1 (en) * 2019-04-28 2020-11-05 杭州泽健医药科技有限公司 Pharmaceutical composition with effect of reducing uric acid
WO2020221192A1 (en) * 2019-04-28 2020-11-05 杭州泽健医药科技有限公司 Pharmaceutical composition having uric acid-lowering and anti-fatigue effects
CN112369609A (en) * 2020-10-30 2021-02-19 云南奥咖生物技术有限公司 Functional food capable of reducing uric acid and preparation method thereof
CN114736946A (en) * 2022-06-10 2022-07-12 广东海洋大学 Preparation method and application of marine fish oligopeptide with functions of resisting fatigue and reducing uric acid
CN117100836A (en) * 2023-10-16 2023-11-24 健码制药(广东)有限公司 Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099846A1 (en) * 2003-05-30 2007-05-03 Lytone Enterprise, Inc. Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide
JP2009102248A (en) * 2007-10-22 2009-05-14 Lytone Enterpprise Inc Pharmaceutical composition for rapidly decreasing uric acid in blood and package, and use of anserine for rapidly decreasing uric acid in blood
CN105126067A (en) * 2015-09-30 2015-12-09 北京知蜂堂蜂产品有限公司 Composition for reducing uric acid and application thereof
CN105380962A (en) * 2015-12-11 2016-03-09 汤臣倍健股份有限公司 Uric acid reducing composition and preparation thereof
CN106135907A (en) * 2015-04-11 2016-11-23 青岛贝尔特生物科技有限公司 A kind of alimentation composition contributing to resisting fatigue
CN106805234A (en) * 2016-12-19 2017-06-09 江苏红瑞制药有限公司 A kind of anti-trioxypurine food compositions
CN109122859A (en) * 2018-11-01 2019-01-04 威海健康生生物科技有限公司 Anti-trioxypurine composition and the preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323675C (en) * 2004-01-19 2007-07-04 张冰 Novel usage of chicory aqueous extract
CN105029447B (en) * 2015-08-11 2019-03-22 湖南科尔生物技术有限公司 A kind of ocean fish oligopeptide powder containing active probiotic
CN105614860A (en) * 2016-01-22 2016-06-01 湖南营养树科技有限公司 Probiotic compound oligopeptide nutritional supplement capable of lowering uric acid
CN107594520A (en) * 2017-09-20 2018-01-19 湖南慧泽生物医药科技有限公司 A kind of formula food eaten for patient with gout
CN108841908A (en) * 2018-08-03 2018-11-20 福建中医药大学 A kind of preparation method with the active marine oligopeptide of anti-trioxypurine
CN110038119A (en) * 2019-04-28 2019-07-23 杭州泽健医药科技有限公司 A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099846A1 (en) * 2003-05-30 2007-05-03 Lytone Enterprise, Inc. Composition containing dipeptide of histidine and alanine for reducing uric acid and method for reducing uric acid using the dipeptide
JP2009102248A (en) * 2007-10-22 2009-05-14 Lytone Enterpprise Inc Pharmaceutical composition for rapidly decreasing uric acid in blood and package, and use of anserine for rapidly decreasing uric acid in blood
CN106135907A (en) * 2015-04-11 2016-11-23 青岛贝尔特生物科技有限公司 A kind of alimentation composition contributing to resisting fatigue
CN105126067A (en) * 2015-09-30 2015-12-09 北京知蜂堂蜂产品有限公司 Composition for reducing uric acid and application thereof
CN105380962A (en) * 2015-12-11 2016-03-09 汤臣倍健股份有限公司 Uric acid reducing composition and preparation thereof
CN106805234A (en) * 2016-12-19 2017-06-09 江苏红瑞制药有限公司 A kind of anti-trioxypurine food compositions
CN109122859A (en) * 2018-11-01 2019-01-04 威海健康生生物科技有限公司 Anti-trioxypurine composition and the preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李怡芳等: "营养型鸡精抗疲劳作用的研究现状", 《今日药学》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221184A1 (en) * 2019-04-28 2020-11-05 杭州泽健医药科技有限公司 Pharmaceutical composition with effect of reducing uric acid
WO2020221192A1 (en) * 2019-04-28 2020-11-05 杭州泽健医药科技有限公司 Pharmaceutical composition having uric acid-lowering and anti-fatigue effects
CN112369609A (en) * 2020-10-30 2021-02-19 云南奥咖生物技术有限公司 Functional food capable of reducing uric acid and preparation method thereof
CN114736946A (en) * 2022-06-10 2022-07-12 广东海洋大学 Preparation method and application of marine fish oligopeptide with functions of resisting fatigue and reducing uric acid
CN117100836A (en) * 2023-10-16 2023-11-24 健码制药(广东)有限公司 Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue
CN117100836B (en) * 2023-10-16 2024-01-26 健码制药(广东)有限公司 Ganoderma lucidum and fructus alpiniae oxyphyllae marine fish oligopeptide composition and application thereof in preventing or treating hyperuricemia and resisting fatigue

Also Published As

Publication number Publication date
WO2020221192A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CN110038119A (en) A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect
CN101822383B (en) Functionality nutritional meal replacing food suitable for tumor patient and preparation method thereof
CN102077936B (en) Special sea dietary food for diabetics
CN102077940B (en) Special dietary marine food for patients with coronary heart disease
CN102077934B (en) Special dietary marine food for patients with high blood pressure
CN107183705A (en) A kind of relax bowel improves the functional food of constipation
CN102526478B (en) Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar
CN108175089A (en) A kind of full nutrient formulation liquid suitable for diabetic
CN110051002A (en) A kind of pharmaceutical composition with anti-trioxypurine effect
CN102077937A (en) Special dietary seafood special for young and middle-aged women
CN102077944B (en) Marine special dietary food special for prostate patient
CN107397208A (en) Using fish glue as functional food of principal component and application thereof
CN109247585A (en) A kind of full nutrition special medicine purposes formula food for trauma patient
CN107616507A (en) A kind of ocean polypeptide spy&#39;s dietary seafood for chornic arthritis edible for patients
CN108782679A (en) A kind of weight-reducing intervention is dry and preparation method thereof for refreshment
CN110354236A (en) A kind of pharmaceutical composition and preparation method thereof for treating sympotoms caused by cold factors
CN102077943B (en) Seafood for special dietary uses for hypomnesia patients
CN102389562A (en) Traditional Chinese medicine composition for treating indigestion in children
CN102335222B (en) Pharmaceutical composition for adjusting blood fat and preparation process thereof
CN108771081A (en) Haematococcus pluvialis citrus fruit fibres compound solid beverage of weight-reducing and preparation method thereof
CN105191859A (en) Production method of low-cholesterol potassium-rich carotene-rich egg
CN108851071A (en) Sea-buckthorn VP alimentation composition and its preparation method and application
Mokolensang et al. Incorporation of macroalgae to fish feed lowers allergenic properties in fish: An opinion study
WO2011142489A1 (en) Natural food composition for improving constipation, prescribed on the basis of the physical constitution of a patient
Gryszkin et al. Ganotherapy in sports

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190723

RJ01 Rejection of invention patent application after publication